$ARWR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ARROWHEAD PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ARROWHEAD PHARMACEUTICALS, INC.. Get notifications about new insider transactions in ARROWHEAD PHARMACEUTICALS, INC. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 09 2018 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Sell | S | 14.35 | 76,200 | 1,093,470 | 1,727,755 | 1.8 M to 1.7 M (-4.22 %) |
| Oct 23 2018 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Gift | G | 0.00 | 3,870 | 0 | 151,130 | 155 K to 151.1 K (-2.50 %) |
| Oct 23 2018 | ARWR | ARROWHEAD PHARMACE ... | Leone Peter Brian | VP, Strategic Bus. ... | Option Exercise | M | 7.75 | 66,762 | 517,406 | 88,863 | |
| Oct 23 2018 | ARWR | ARROWHEAD PHARMACE ... | Leone Peter Brian | VP, Strategic Bus. ... | Option Exercise | M | 6.15 | 34,375 | 211,406 | 155,625 | |
| Oct 23 2018 | ARWR | ARROWHEAD PHARMACE ... | Leone Peter Brian | VP, Strategic Bus. ... | Option Exercise | M | 2.79 | 30,000 | 83,700 | 190,000 | |
| Oct 23 2018 | ARWR | ARROWHEAD PHARMACE ... | Leone Peter Brian | VP, Strategic Bus. ... | Sell | S | 13.49 | 131,137 | 1,769,038 | 130,000 | 261.1 K to 130 K (-50.22 %) |
| Oct 23 2018 | ARWR | ARROWHEAD PHARMACE ... | Leone Peter Brian | VP, Strategic Bus. ... | Buy | M | 7.75 | 66,762 | 517,406 | 261,137 | 194.4 K to 261.1 K (+34.35 %) |
| Oct 23 2018 | ARWR | ARROWHEAD PHARMACE ... | Leone Peter Brian | VP, Strategic Bus. ... | Buy | M | 6.15 | 34,375 | 211,406 | 194,375 | 160 K to 194.4 K (+21.48 %) |
| Oct 23 2018 | ARWR | ARROWHEAD PHARMACE ... | Leone Peter Brian | VP, Strategic Bus. ... | Buy | M | 2.79 | 30,000 | 83,700 | 160,000 | 130 K to 160 K (+23.08 %) |
| Sep 10 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Option Exercise | M | 4.75 | 20,000 | 95,000 | 243,000 | |
| Sep 10 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Option Exercise | M | 2.62 | 25,000 | 65,500 | 263,000 | |
| Sep 10 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Sell | S | 21.01 | 20,000 | 420,200 | 310,815 | 330.8 K to 310.8 K (-6.05 %) |
| Sep 10 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Sell | S | 18.00 | 25,000 | 450,000 | 330,815 | 355.8 K to 330.8 K (-7.03 %) |
| Sep 10 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Buy | M | 4.75 | 20,000 | 95,000 | 355,815 | 335.8 K to 355.8 K (+5.96 %) |
| Sep 10 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Buy | M | 2.62 | 25,000 | 65,500 | 335,815 | 310.8 K to 335.8 K (+8.04 %) |
| Sep 05 2018 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Sell | S | 14.45 | 64,834 | 936,851 | 1,803,955 | 1.9 M to 1.8 M (-3.47 %) |
| Sep 05 2018 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Sell | S | 14.45 | 100,000 | 1,445,000 | 1,868,789 | 2 M to 1.9 M (-5.08 %) |
| Jun 20 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Option Exercise | M | 2.01 | 20,000 | 40,200 | 288,000 | |
| Jun 20 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Sell | S | 14.01 | 20,000 | 280,200 | 310,815 | 330.8 K to 310.8 K (-6.05 %) |
| Jun 20 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Buy | M | 2.01 | 20,000 | 40,200 | 330,815 | 310.8 K to 330.8 K (+6.43 %) |
| Jun 20 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Option Exercise | M | 2.01 | 20,000 | 40,200 | 288,000 | |
| Jun 20 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Sell | S | 14.01 | 20,000 | 280,200 | 310,815 | 330.8 K to 310.8 K (-6.05 %) |
| Jun 20 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Buy | M | 2.01 | 20,000 | 40,200 | 330,815 | 310.8 K to 330.8 K (+6.43 %) |
| Jun 01 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Option Exercise | M | 2.01 | 12,600 | 25,326 | 308,000 | |
| Jun 01 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Option Exercise | M | 2.01 | 1,400 | 2,814 | 320,600 | |
| Jun 01 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Sell | S | 11.00 | 12,600 | 138,600 | 310,815 | 323.4 K to 310.8 K (-3.90 %) |
| Jun 01 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Buy | M | 2.01 | 12,600 | 25,326 | 323,415 | 310.8 K to 323.4 K (+4.05 %) |
| Jun 01 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Sell | S | 11.00 | 1,400 | 15,400 | 310,815 | 312.2 K to 310.8 K (-0.45 %) |
| Jun 01 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Buy | M | 2.01 | 1,400 | 2,814 | 312,215 | 310.8 K to 312.2 K (+0.45 %) |
| Apr 25 2018 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Sell | S | 6.63 | 25,000 | 165,750 | 155,000 | 180 K to 155 K (-13.89 %) |
| Mar 27 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Option Exercise | M | 2.01 | 20,000 | 40,200 | 322,000 | |
| Mar 27 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Sell | S | 8.00 | 20,000 | 160,000 | 310,815 | 330.8 K to 310.8 K (-6.05 %) |
| Mar 27 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Buy | M | 2.01 | 20,000 | 40,200 | 330,815 | 310.8 K to 330.8 K (+6.43 %) |
| Mar 16 2018 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Sell | S | 7.40 | 26,000 | 192,400 | 1,968,789 | 2 M to 2 M (-1.30 %) |
| Mar 15 2018 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Sell | S | 7.41 | 100,000 | 741,000 | 1,994,789 | 2.1 M to 2 M (-4.77 %) |
| Mar 15 2018 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Sell | S | 7.44 | 100,000 | 744,000 | 2,094,789 | 2.2 M to 2.1 M (-4.56 %) |
| Mar 15 2018 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Sell | S | 7.43 | 100,000 | 743,000 | 2,194,789 | 2.3 M to 2.2 M (-4.36 %) |
| Mar 05 2018 | ARWR | ARROWHEAD PHARMACE ... | GIVEN BRUCE D | Chief Operating Off ... | Sell | S | 6.73 | 20,000 | 134,600 | 908,356 | 928.4 K to 908.4 K (-2.15 %) |
| Mar 05 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Payment of Exercise | F | 6.66 | 8,208 | 54,665 | 310,815 | 319 K to 310.8 K (-2.57 %) |
| Jan 03 2018 | ARWR | ARROWHEAD PHARMACE ... | FRYKMAN EDWARD W | Director | Grant | A | 0.00 | 25,000 | 0 | 148,852 | 123.9 K to 148.9 K (+20.19 %) |
| Jan 03 2018 | ARWR | ARROWHEAD PHARMACE ... | Waddill William D. | Director | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
| Jan 03 2018 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Grant | A | 0.00 | 30,000 | 0 | 185,000 | 155 K to 185 K (+19.35 %) |
| Jan 03 2018 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Grant | A | 0.00 | 30,000 | 0 | 180,000 | 150 K to 180 K (+20.00 %) |
| Jan 03 2018 | ARWR | ARROWHEAD PHARMACE ... | Leone Peter Brian | VP, Strategic Bus. ... | Grant | A | 0.00 | 40,000 | 0 | 130,000 | 90 K to 130 K (+44.44 %) |
| Jan 03 2018 | ARWR | ARROWHEAD PHARMACE ... | O'Brien Patrick | General Counsel | Grant | A | 0.00 | 60,000 | 0 | 235,000 | 175 K to 235 K (+34.29 %) |
| Jan 03 2018 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Grant | A | 0.00 | 75,000 | 0 | 319,023 | 244 K to 319 K (+30.73 %) |
| Jan 03 2018 | ARWR | ARROWHEAD PHARMACE ... | GIVEN BRUCE D | Chief Operating Off ... | Sell | S | 3.69 | 20,000 | 73,800 | 928,356 | 948.4 K to 928.4 K (-2.11 %) |
| Jan 03 2018 | ARWR | ARROWHEAD PHARMACE ... | GIVEN BRUCE D | Chief Operating Off ... | Grant | A | 0.00 | 175,000 | 0 | 948,356 | 773.4 K to 948.4 K (+22.63 %) |
| Jan 03 2018 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Grant | A | 0.00 | 500,000 | 0 | 2,294,789 | 1.8 M to 2.3 M (+27.86 %) |
| Apr 14 2017 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Grant | A | 0.00 | 978,000 | 0 | 1,794,789 | 816.8 K to 1.8 M (+119.74 %) |
| Jan 04 2017 | ARWR | ARROWHEAD PHARMACE ... | Ferrari Mauro | Director | Grant | A | 0.00 | 50,000 | 0 | 62,768 | 12.8 K to 62.8 K (+391.60 %) |
| Jan 04 2017 | ARWR | ARROWHEAD PHARMACE ... | FRYKMAN EDWARD W | Director | Grant | A | 0.00 | 50,000 | 0 | 123,852 | 73.9 K to 123.9 K (+67.70 %) |
| Jan 04 2017 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Grant | A | 0.00 | 80,000 | 0 | 155,000 | 75 K to 155 K (+106.67 %) |
| Jan 04 2017 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Grant | A | 0.00 | 80,000 | 0 | 150,000 | 70 K to 150 K (+114.29 %) |
| Jan 04 2017 | ARWR | ARROWHEAD PHARMACE ... | Leone Peter Brian | VP, Strategy & Prog ... | Grant | A | 0.00 | 90,000 | 0 | 90,000 | 0 to 90 K |
| Jan 04 2017 | ARWR | ARROWHEAD PHARMACE ... | O'Brien Patrick | General Counsel | Grant | A | 0.00 | 145,000 | 0 | 175,000 | 30 K to 175 K (+483.33 %) |
| Jan 04 2017 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Grant | A | 0.00 | 145,000 | 0 | 260,689 | 115.7 K to 260.7 K (+125.34 %) |
| Jan 04 2017 | ARWR | ARROWHEAD PHARMACE ... | GIVEN BRUCE D | Chief Operating Off ... | Grant | A | 0.00 | 380,000 | 0 | 773,356 | 393.4 K to 773.4 K (+96.60 %) |
| Dec 15 2016 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Payment of Exercise | F | 1.27 | 300,444 | 381,564 | 816,789 | 1.1 M to 816.8 K (-26.89 %) |
| Oct 18 2016 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Sell | S | 6.72 | 12,000 | 80,640 | 70,000 | 82 K to 70 K (-14.63 %) |
| Oct 18 2016 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Gift | G | 0.00 | 8,000 | 0 | 82,000 | 90 K to 82 K (-8.89 %) |
| Aug 24 2016 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Option Exercise | M | 2.01 | 6,900 | 13,869 | 342,000 | |
| Aug 24 2016 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Option Exercise | M | 2.01 | 13,100 | 26,331 | 348,900 | |
| Aug 24 2016 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Sell | S | 8.00 | 6,900 | 55,200 | 115,689 | 122.6 K to 115.7 K (-5.63 %) |
| Aug 24 2016 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Buy | M | 2.01 | 6,900 | 13,869 | 122,589 | 115.7 K to 122.6 K (+5.96 %) |
| Aug 24 2016 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Sell | S | 8.00 | 13,100 | 104,800 | 115,689 | 128.8 K to 115.7 K (-10.17 %) |
| Aug 24 2016 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Buy | M | 2.01 | 13,100 | 26,331 | 128,789 | 115.7 K to 128.8 K (+11.32 %) |
| Jul 05 2016 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Option Exercise | X | 5.09 | 15,772 | 80,279 | 0 | |
| Jul 05 2016 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Buy | M | 5.09 | 15,772 | 80,279 | 1,117,233 | 1.1 M to 1.1 M (+1.43 %) |
| Jun 15 2016 | ARWR | ARROWHEAD PHARMACE ... | Ferrari Mauro | Director | Grant | A | 0.00 | 8,517 | 0 | 12,768 | 4.3 K to 12.8 K (+200.35 %) |
| Mar 08 2016 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Payment of Exercise | F | 4.33 | 6,263 | 27,119 | 115,689 | 122 K to 115.7 K (-5.14 %) |
| Mar 08 2016 | ARWR | ARROWHEAD PHARMACE ... | GIVEN BRUCE D | Chief Operating Off ... | Payment of Exercise | F | 4.33 | 13,675 | 59,213 | 393,356 | 407 K to 393.4 K (-3.36 %) |
| Feb 09 2016 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Payment of Exercise | F | 3.46 | 13,048 | 45,146 | 121,952 | 135 K to 122 K (-9.67 %) |
| Feb 09 2016 | ARWR | ARROWHEAD PHARMACE ... | GIVEN BRUCE D | Chief Operating Off ... | Payment of Exercise | F | 3.46 | 17,969 | 62,173 | 407,031 | 425 K to 407 K (-4.23 %) |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | FRYKMAN EDWARD W | Director | Grant | A | 0.00 | 25,000 | 0 | 73,852 | 48.9 K to 73.9 K (+51.17 %) |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Grant | A | 0.00 | 30,000 | 0 | 75,000 | 45 K to 75 K (+66.67 %) |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Grant | A | 0.00 | 35,000 | 0 | 90,000 | 55 K to 90 K (+63.64 %) |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | Leone Peter Brian | VP, Strategy & Prog ... | Option Exercise | A | 6.15 | 50,000 | 307,500 | 220,000 | |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | O'Brien Patrick | General Counsel | Option Exercise | A | 6.15 | 60,000 | 369,000 | 150,000 | |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | Lewis David L. | Chief Scientific Of ... | Option Exercise | A | 6.15 | 85,000 | 522,750 | 472,500 | |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | GIVEN BRUCE D | Chief Operating Off ... | Option Exercise | A | 6.15 | 60,000 | 369,000 | 556,000 | |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | GIVEN BRUCE D | Chief Operating Off ... | Grant | A | 0.00 | 150,000 | 0 | 425,000 | 275 K to 425 K (+54.55 %) |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Option Exercise | A | 6.15 | 40,000 | 246,000 | 362,000 | |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Grant | A | 0.00 | 50,000 | 0 | 135,000 | 85 K to 135 K (+58.82 %) |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Sell | S | 6.13 | 23,347 | 143,117 | 85,000 | 108.3 K to 85 K (-21.55 %) |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | Chief Financial Off ... | Payment of Exercise | F | 6.13 | 13,153 | 80,628 | 108,347 | 121.5 K to 108.3 K (-10.83 %) |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Option Exercise | A | 6.15 | 80,000 | 492,000 | 1,166,466 | |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Grant | A | 0.00 | 540,000 | 0 | 1,101,461 | 561.5 K to 1.1 M (+96.18 %) |
| Jan 04 2016 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | Chief Executive Off ... | Payment of Exercise | F | 6.13 | 58,712 | 359,905 | 561,461 | 620.2 K to 561.5 K (-9.47 %) |
| Mar 10 2015 | ARWR | ARROWHEAD PHARMACE ... | Lewis David L. | Chief Scientific Of ... | Option Exercise | A | 7.75 | 100,000 | 775,000 | 387,500 | |
| Mar 06 2015 | ARWR | ARROWHEAD PHARMACE ... | GIVEN BRUCE D | Chief Operating Off ... | Option Exercise | A | 7.75 | 60,000 | 465,000 | 496,000 | |
| Mar 06 2015 | ARWR | ARROWHEAD PHARMACE ... | GIVEN BRUCE D | Chief Operating Off ... | Grant | A | 0.00 | 150,000 | 0 | 275,000 | 125 K to 275 K (+120.00 %) |
| Mar 06 2015 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | President and CEO | Option Exercise | A | 7.75 | 300,000 | 2,325,000 | 1,086,466 | |
| Mar 06 2015 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | President and CEO | Grant | A | 0.00 | 360,000 | 0 | 620,173 | 260.2 K to 620.2 K (+138.37 %) |
| Mar 06 2015 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | CFO | Option Exercise | A | 7.75 | 50,000 | 387,500 | 322,000 | |
| Mar 06 2015 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | CFO | Grant | A | 0.00 | 50,000 | 0 | 121,500 | 71.5 K to 121.5 K (+69.93 %) |
| Mar 06 2015 | ARWR | ARROWHEAD PHARMACE ... | McKenney Charles | Director | Grant | A | 0.00 | 25,000 | 0 | 42,220 | 17.2 K to 42.2 K (+145.18 %) |
| Mar 06 2015 | ARWR | ARROWHEAD PHARMACE ... | FRYKMAN EDWARD W | Director | Grant | A | 0.00 | 25,000 | 0 | 48,852 | 23.9 K to 48.9 K (+104.81 %) |
| Mar 06 2015 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Grant | A | 0.00 | 30,000 | 0 | 45,000 | 15 K to 45 K (+200.00 %) |
| Mar 06 2015 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Grant | A | 0.00 | 35,000 | 0 | 55,000 | 20 K to 55 K (+175.00 %) |
| Jan 14 2015 | ARWR | ARROWHEAD PHARMACE ... | Ferrari Mauro | Director | Buy | P | 7.62 | 400 | 3,047 | 4,251 | 3.9 K to 4.3 K (+10.39 %) |
| Jan 14 2015 | ARWR | ARROWHEAD PHARMACE ... | Ferrari Mauro | Director | Buy | P | 6.19 | 1,900 | 11,761 | 3,851 | 2 K to 3.9 K (+97.39 %) |
| Jan 07 2015 | ARWR | ARROWHEAD PHARMACE ... | Lewis David L. | Chief Scientific Of ... | Option Exercise | M | 2.01 | 15,000 | 30,150 | 287,500 | |
| Jan 07 2015 | ARWR | ARROWHEAD PHARMACE ... | Lewis David L. | Chief Scientific Of ... | Sell | S | 8.01 | 15,000 | 120,104 | 0 | 15 K to 0 (-100.00 %) |
| Jan 07 2015 | ARWR | ARROWHEAD PHARMACE ... | Lewis David L. | Chief Scientific Of ... | Buy | M | 2.01 | 15,000 | 30,150 | 15,000 | 0 to 15 K |
| Dec 04 2014 | ARWR | ARROWHEAD PHARMACE ... | O'Brien Patrick | General Counsel | Option Exercise | A | 5.22 | 90,000 | 469,800 | 90,000 | |
| Dec 04 2014 | ARWR | ARROWHEAD PHARMACE ... | O'Brien Patrick | General Counsel | Grant | A | 0.00 | 30,000 | 0 | 30,000 | 0 to 30 K |
| Oct 15 2014 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | President and CEO | Buy | P | 6.32 | 16,000 | 101,120 | 260,173 | 244.2 K to 260.2 K (+6.55 %) |
| Oct 01 2014 | ARWR | ARROWHEAD PHARMACE ... | McKenney Charles | Director | Option Exercise | M | 5.19 | 2,500 | 12,975 | 50,500 | |
| Oct 01 2014 | ARWR | ARROWHEAD PHARMACE ... | McKenney Charles | Director | Sell | S | 14.70 | 2,500 | 36,749 | 17,220 | 19.7 K to 17.2 K (-12.68 %) |
| Oct 01 2014 | ARWR | ARROWHEAD PHARMACE ... | McKenney Charles | Director | Buy | M | 5.19 | 2,500 | 12,975 | 19,720 | 17.2 K to 19.7 K (+14.52 %) |
| Sep 30 2014 | ARWR | ARROWHEAD PHARMACE ... | Lewis David L. | Chief Scientific Of ... | Option Exercise | M | 2.01 | 15,000 | 30,150 | 302,500 | |
| Sep 30 2014 | ARWR | ARROWHEAD PHARMACE ... | Lewis David L. | Chief Scientific Of ... | Sell | S | 15.02 | 15,000 | 225,350 | 0 | 15 K to 0 (-100.00 %) |
| Sep 30 2014 | ARWR | ARROWHEAD PHARMACE ... | Lewis David L. | Chief Scientific Of ... | Buy | M | 2.01 | 15,000 | 30,150 | 15,000 | 0 to 15 K |
| Sep 30 2014 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Option Exercise | M | 2.19 | 2,000 | 4,380 | 65,000 | |
| Sep 30 2014 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Sell | S | 15.24 | 2,000 | 30,480 | 20,000 | 22 K to 20 K (-9.09 %) |
| Sep 30 2014 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Buy | M | 2.19 | 2,000 | 4,380 | 22,000 | 20 K to 22 K (+10.00 %) |
| Aug 19 2014 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Option Exercise | M | 2.01 | 5,000 | 10,050 | 67,000 | |
| Aug 19 2014 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Sell | S | 13.90 | 5,000 | 69,501 | 20,000 | 25 K to 20 K (-20.00 %) |
| Aug 19 2014 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Buy | M | 2.01 | 5,000 | 10,050 | 25,000 | 20 K to 25 K (+25.00 %) |
| Aug 19 2014 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | CFO | Option Exercise | M | 7.00 | 25,000 | 175,000 | 272,000 | |
| Aug 19 2014 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | CFO | Option Exercise | M | 5.19 | 15,000 | 77,850 | 297,000 | |
| Aug 19 2014 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | CFO | Sell | S | 14.02 | 40,000 | 560,860 | 71,500 | 111.5 K to 71.5 K (-35.87 %) |
| Aug 19 2014 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | CFO | Buy | M | 7.00 | 25,000 | 175,000 | 111,500 | 86.5 K to 111.5 K (+28.90 %) |
| Aug 19 2014 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | CFO | Buy | M | 5.19 | 15,000 | 77,850 | 86,500 | 71.5 K to 86.5 K (+20.98 %) |
| Jun 10 2014 | ARWR | ARROWHEAD PHARMACE ... | McKenney Charles | Director | Option Exercise | M | 2.62 | 10,000 | 26,200 | 53,000 | |
| Jun 10 2014 | ARWR | ARROWHEAD PHARMACE ... | McKenney Charles | Director | Option Exercise | M | 2.19 | 12,000 | 26,280 | 63,000 | |
| Jun 10 2014 | ARWR | ARROWHEAD PHARMACE ... | McKenney Charles | Director | Sell | S | 14.32 | 22,000 | 315,005 | 17,220 | 39.2 K to 17.2 K (-56.09 %) |
| Jun 10 2014 | ARWR | ARROWHEAD PHARMACE ... | McKenney Charles | Director | Buy | M | 2.62 | 10,000 | 26,200 | 39,220 | 29.2 K to 39.2 K (+34.22 %) |
| Jun 10 2014 | ARWR | ARROWHEAD PHARMACE ... | McKenney Charles | Director | Buy | M | 2.19 | 12,000 | 26,280 | 29,220 | 17.2 K to 29.2 K (+69.69 %) |
| Feb 12 2014 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | CFO | Option Exercise | M | 2.01 | 16,000 | 32,160 | 312,000 | |
| Feb 12 2014 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | CFO | Sell | S | 18.77 | 16,000 | 300,290 | 71,500 | 87.5 K to 71.5 K (-18.29 %) |
| Feb 12 2014 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | CFO | Buy | M | 2.01 | 16,000 | 32,160 | 87,500 | 71.5 K to 87.5 K (+22.38 %) |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | FRYKMAN EDWARD W | Director | Option Exercise | M | 10.00 | 5,000 | 50,000 | 77,500 | |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | FRYKMAN EDWARD W | Director | Sell | S | 15.98 | 3,148 | 50,296 | 23,852 | 27 K to 23.9 K (-11.66 %) |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | FRYKMAN EDWARD W | Director | Buy | M | 10.00 | 5,000 | 50,000 | 27,000 | 22 K to 27 K (+22.73 %) |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | FRYKMAN EDWARD W | Director | Grant | A | 0.00 | 15,000 | 0 | 22,000 | 7 K to 22 K (+214.29 %) |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | PERRY MICHAEL S | Director | Grant | A | 0.00 | 15,000 | 0 | 15,000 | 0 to 15 K |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | McKenney Charles | Director | Grant | A | 0.00 | 15,000 | 0 | 17,220 | 2.2 K to 17.2 K (+675.68 %) |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | GIVEN DOUGLAS B | Director | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | GIVEN BRUCE D | Chief Operating Off ... | Option Exercise | A | 14.54 | 50,000 | 727,000 | 436,000 | |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | GIVEN BRUCE D | Chief Operating Off ... | Grant | A | 0.00 | 125,000 | 0 | 125,000 | 0 to 125 K |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | President and CEO | Option Exercise | A | 14.54 | 60,000 | 872,400 | 786,466 | |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | Anzalone Christopher Richard | President and CEO | Grant | A | 0.00 | 210,000 | 0 | 244,173 | 34.2 K to 244.2 K (+614.52 %) |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | Lewis David L. | Chief Scientific Of ... | Option Exercise | A | 14.54 | 120,000 | 1,744,800 | 317,500 | |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | CFO | Option Exercise | A | 14.54 | 50,000 | 727,000 | 328,000 | |
| Feb 10 2014 | ARWR | ARROWHEAD PHARMACE ... | Myszkowski Kenneth Allen | CFO | Grant | A | 0.00 | 70,000 | 0 | 71,500 | 1.5 K to 71.5 K (+4,666.67 %) |
| Jan 06 2014 | ARWR | ARROWHEAD PHARMACE ... | Lewis David L. | Chief Scientific Of ... | Option Exercise | M | 2.62 | 2,500 | 6,550 | 197,500 | |
| Jan 06 2014 | ARWR | ARROWHEAD PHARMACE ... | Lewis David L. | Chief Scientific Of ... | Option Exercise | M | 5.19 | 2,500 | 12,975 | 200,000 | |
| Jan 06 2014 | ARWR | ARROWHEAD PHARMACE ... | Lewis David L. | Chief Scientific Of ... | Option Exercise | M | 4.60 | 10,000 | 46,000 | 202,500 |